TCGA-CU-A5W6-01A-11R-A28M-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 1.839684625
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.370
- BILE_ACID_METABOLISM+0.340
- CHOLESTEROL_HOMEOSTASIS+0.330
- PROTEIN_SECRETION+0.280
- PANCREAS_BETA_CELLS+0.260
- ADIPOGENESIS+0.240
- SPERMATOGENESIS+0.240
- XENOBIOTIC_METABOLISM+0.240
- MTORC1_SIGNALING+0.230
- UV_RESPONSE_UP+0.220
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
- MITOTIC_SPINDLE-0.420
- UV_RESPONSE_DN-0.350
- TGF_BETA_SIGNALING-0.330
- WNT_BETA_CATENIN_SIGNALING-0.330
- ALLOGRAFT_REJECTION-0.300
- G2M_CHECKPOINT-0.300
- APICAL_JUNCTION-0.290
- E2F_TARGETS-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR4296070 | — | cohortA1 | 0.892 |
| 2 | SRR8518413 | — | F | 0.820 |
| 3 | MBCProject_3946_T5A_RNA | — | C | 0.806 |
| 4 | BS_B6M763JS | subependymal giant cell astrocytoma(SEGA) | — | 0.795 |
| 5 | SRR8518189 | — | F | 0.779 |
| 6 | TCGA-B6-A0RO-01A-22R-A084-07 | — | C | 0.774 |
| 7 | TCGA-C8-A133-01A-32R-A12D-07 | — | B | 0.769 |
| 8 | TCGA-49-4486-01A-01R-1206-07 | — | cohortA2 | 0.767 |
| 9 | TCGA-OR-A5JL-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.764 |
| 10 | SRR8942970 | — | — | 0.764 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.370 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.340 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.330 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.280 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.240 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.240 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.220 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.170 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.090 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.060 | Temsirolimus | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.030 | Idelalisib | — uncovered |